Albemarle Corporation reported better-than-expected second-quarter earnings for 2025, driven by increased lithium demand and volume growth. The company posted revenue of $1.33 billion, surpassing the estimated $1.22 billion, and an adjusted earnings per share of $0.11, compared to an anticipated loss of $0.78 per share. Despite a slump in lithium prices, Albemarle has implemented cost-cutting measures and reduced its capital expenditure outlook for 2025 to a range of $650 million to $700 million. The company maintains its full-year earnings assumptions based on lithium pricing at $9 per kilogram and expects to generate positive free cash flow in 2025. These financial results have contributed to a surge in Albemarle's shares.
$BBIO catalysts ■ Quarterly: Commercial Attruby results next one Aug 5 ■ 2H25: BBP-418 Interim analysis ■ 2H25: Encaleret Phase 3 topline ■ 1Q26: Infigratinib's Propel3 Phase 3 topline https://t.co/iIeD9FUicC
$SNY Amlitelimab has Ph3 COAST 1 initial AD data on track for 2H25 with full data in 1H26. Importantly, SNY emphasized they continue to expect the first data from amlitelimab's (OX-40L mAb) Ph3 AD program in 2H25. Specifically, the first readout is expected to be from 24-week Ph3
$ALNY - new projections / catalysts https://t.co/jrWtHitmvX https://t.co/JAnc2OfQzq